slides · global inventory
List
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,471
Current window 39,421-39,450
Pages 3,683
Rows per page 30
Component
39,421-39,450 of 110,471
06
The slide uses a donut chart to visualize the revenue split between the two segments.Advantage Solutions | Investor Presentation Deck | 27 slides · Advantage Solutions
Pitch deck Investor relations 2 hits
07
The slide uses a donut chart to illustrate market concentration and lists key service offerings for four business units.Advantage Solutions | Investor Presentation Deck | 27 slides · Advantage Solutions
Pitch deck Investor relations Beat · Market Size2 hits
19
Includes a stacked bar chart showing debt maturity and a table detailing debt instruments and equity components.Advantage Solutions | Investor Presentation Deck | 27 slides · Advantage Solutions
Pitch deck Investor relations 2 hits
05
Advantage Solutions | Results Presentation Deck | 13 slidesAdvantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · OverviewLoop · So What Cascade2 hits
07
Includes a waterfall-style chart showing debt components and a detailed table for debt and equity.Advantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · Capitalization Summary2 hits
04
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Golden Circle2 hits
08
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem2 hits
11
Includes a biological process diagram showing intracellular vs plasma metabolism.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · SolutionLoop · Mece Breakdown2 hits
13
The slide uses two distinct chart types (Kaplan-Meier survival curve and a time-series pharmacodynamic plot) to demonstrate drug efficacy.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution2 hits
14
The slide outlines a two-part clinical trial structure with specific cohorts and patient criteria.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution2 hits
15
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution2 hits
17
Includes a timeline-based progression of symptoms from infancy to adulthood.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 2 hits
18
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 2 hits
23
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 2 hits
13
Aeva | Results Presentation Deck | 14 slidesAeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations Beat · Action2 hits
08
The chart shows a steady upward trend in weekly total prescriptions (TRx) over 73 weeks.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Evidence & Proof2 hits
22
The slide outlines a two-stage clinical development process with specific objectives and assessment criteria for each phase.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Loop · Quick Win Big Bet2 hits
24
The slide outlines the core assets (nemvaleukin alfa, IL-12, IL-18) and the strategic rationale for a spin-off.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations 2 hits
06
Uses a 'Where we are today' vs 'Where we are going' structure to frame the company's evolution.Allbirds | Investor Presentation Deck | 14 slides · Allbirds
Pitch deck Investor relations Beat · RoadmapLoop · Why Now2 hits
11
Allbirds | Investor Presentation Deck | 14 slidesAllbirds | Investor Presentation Deck | 14 slides · Allbirds
Pitch deck Investor relations Beat · Financials2 hits
16
The slide uses a stacked bar chart to illustrate a structural shift in investment strategy.Apollo Global Management | Investor Presentation Deck | 60 slides · Apollo Global Management
Pitch deck Investor relations Beat · Solution2 hits
24
Includes logos of distribution technology partners (iCapital, CAIS, FIGURE, MOTIVE PARTNERS).Apollo Global Management | Investor Presentation Deck | 60 slides · Apollo Global Management
Pitch deck Investor relations Beat · Solution2 hits
04
Includes a legend for technical acronyms at the bottom.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 2 hits
04
The slide uses a circular graphic element to emphasize the 'revolution' in autoimmunity.argenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations Loop · Why Now2 hits
07
The slide uses a waterfall-style bar chart to show quarterly revenue progression, though it is technically a standard bar chart.argenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations Loop · Why Now2 hits
15
Theravance Biopharma | Results Presentation Deck | 31 slidesTheravance Biopharma | Results Presentation Deck | 31 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Future Vision (Gain)2 hits
30
Includes a detailed table for Trelegy Ellipta royalties and milestones by year.Theravance Biopharma | Results Presentation Deck | 31 slides · Theravance Biopharma
Conference presentation Investor relations 2 hits
14
The bridge chart shows a significant drop from 72.2% to 65.1% driven by specific expense and revenue mix factors.XP Inc | Results Presentation Deck | 23 slides · XP Inc
Conference presentation Investor relations Beat · Financials2 hits
15
Includes 2023 estimates and YoY quarterly comparison.XP Inc | Results Presentation Deck | 23 slides · XP Inc
Conference presentation Investor relations Beat · Financials2 hits
05
The slide uses a two-sided marketplace framework to illustrate the value proposition for both sides of the platform.Yelp | Investor Presentation Deck | 42 slides · Yelp
Pitch deck Investor relations Beat · Problem2 hits